Quick Search 
Drugs of the Future
Register or sign in

  
 
  
Volume 45, Issue 1, January 2020, Pages 5-73
 
MONOGRAPHS
 
  
 Infigratinib.
Fibroblast growth factor receptor (FGFR) 1-3 inhibitor, Treatment of cholangiocarcinoma, Treatment of urothelial carcinoma.
Katoh, M., Katoh, M.
Drugs Fut 2020, 45(1): 5
Summary | Full Text: PDF 
 
  
  
 Onvansertib fumarate.
Serine/threonine-protein kinase PLK1 (STPK13) inhibitor, Treatment of prostate cancer, Treatment of colorectal cancer, Treatment of acute myeloid leukemia.
Gras, J.
Drugs Fut 2020, 45(1): 13
Summary | Full Text: PDF 
 
  
  
 Teprotumumab.
Anti-insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, Treatment of thyroid eye disease.
Ferro Desideri, L., Vagge, A., del Noce, C., Nicolo, M., Traverso, C.E.
Drugs Fut 2020, 45(1): 21
Summary | Full Text: PDF 
 
  
 
DRUGLINE
 
  
 Pipeline on the move.
Torramade, E., Molas, G., Tell, M., Presa, A.
Drugs Fut 2020, 45(1): 27
Full Text: PDF 
 
  
  
 NME Digest.
Bofill, X., Cole, P., Fernandez-Forner, D., Torramade, E.
Drugs Fut 2020, 45(1): 39
Full Text: PDF 
 
  
 
MEETING REPORTS
 
  
 Recent Clinical Disclosures and SMR Award. Highlights from The Society for Medicines Research Symposium. London, UK – December 5, 2019.
Brown, P., Butterworth, S., Hann, M.M., Jeffrey, P., Porter, R., Swarbrick, M.E., Ward, S.E.
Drugs Fut 2020, 45(1): 63
Summary | Full Text: PDF 
 
  
  
 World Vaccine Congress Europe 2019. Barcelona, Spain – October 28-31, 2019.
Suria, R.M.
Drugs Fut 2020, 45(1): 71
Summary | Full Text: PDF 
 
  
 
  



© 2020 Clarivate Analytics. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie Policy